de Muralt B, de Tribolet N, Diserens A C, Stavrou D, Mach J P, Carrel S
Eur J Cancer Clin Oncol. 1985 Feb;21(2):207-16. doi: 10.1016/0277-5379(85)90175-0.
The reactivity spectrum of three monoclonal antibodies (Mabs) to human malignant glioma, five Mabs to melanomas and one Mab anti-HLA-DR was investigated by an indirect antibody binding radioimmunoassay on a panel of cells derived from 60 glioma lines, including 47 malignant astrocytomas, 11 low-grade astrocytomas and two malignant ependymomas as well on cells from 12 melanoma, three neuroblastoma, three medulloblastoma, two schwannoma, two retinoblastoma, two choroïd plexus papilloma, ten meningioma and 12 unrelated tumor lines. The anti-glioma Mabs BF7 and GE2 reacted preferentially with gliomas, while the anti-glioma Mab CG12 reacted with gliomas, melanomas, neuroblastomas and medulloblastomas. The five anti-melanoma Mabs reacted with gliomas, neuroblastomas and medulloblastomas. The anti-HLA-DR Mab D1-12 reacted with gliomas, melanomas and some meningiomas. On the basis of the data presented, we describe three different antigenic systems; the first one is glioma-associated, the second one is related to differentiation antigens expressed on cells derived from the neuroectoderm and the third is represented by HLA-DR antigens which are expressed not only on B-lymphoblastoid cells but also on melanomas and gliomas.
采用间接抗体结合放射免疫分析法，在一组来自60个胶质瘤细胞系（包括47个恶性星形细胞瘤、11个低级别星形细胞瘤和2个恶性室管膜瘤）以及12个黑色素瘤、3个神经母细胞瘤、3个髓母细胞瘤、2个神经鞘瘤、2个视网膜母细胞瘤、2个脉络丛乳头状瘤、10个脑膜瘤和12个无关肿瘤细胞系的细胞上，研究了3种抗人恶性胶质瘤单克隆抗体（Mab）、5种抗黑色素瘤Mab和1种抗HLA - DR Mab的反应谱。抗胶质瘤Mab BF7和GE2优先与胶质瘤发生反应，而抗胶质瘤Mab CG12则与胶质瘤、黑色素瘤、神经母细胞瘤和髓母细胞瘤发生反应。5种抗黑色素瘤Mab与胶质瘤、神经母细胞瘤和髓母细胞瘤发生反应。抗HLA - DR Mab D1 - 12与胶质瘤、黑色素瘤和一些脑膜瘤发生反应。根据所呈现的数据，我们描述了三种不同的抗原系统；第一种是胶质瘤相关的，第二种与神经外胚层来源细胞上表达的分化抗原有关，第三种由HLA - DR抗原代表，其不仅在B淋巴细胞样细胞上表达，也在黑色素瘤和胶质瘤上表达。
